ג'יוטריף 30 מ"ג - Giotrif 30 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | GIOTRIF as monotherapy is indicated for the treatment of: ⢠EGFR TKI-na?ve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);⢠locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
| ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×'×××ר××£ 30 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, GERMANY |
| ×©× ××¢× ×ר×ש×× | BOEHRINGER INGELHEIM ISRAEL LTD. |
| ר×ש××× | ת×ר×× ××ש×: 08/2013. ר×ש××× ×ת×ר××: 03/2014 |
| ת×ר×× ×¢×××× ××ר×× | 14/02/19 |
השינוי האחרון נעשה בֹ־19 ביוני 2025 ב־10:45